AURA at a glance
Aura Biosciences, Inc. (AURA, SEC CIK 1501796) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Aura Biosciences, Inc. (AURA) shares worth $117.9 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Hopkins Janet Jill on November 16, 2026 of 16,903 shares at $7.05 per share.
- In the last 90 days, AURA insiders reported 0 open-market purchases ($0) and 1 open-market sale ($119K) on Form 4, a net sale of $119K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$119K
- 13F holders
- 25 funds
- $117.9M · −2 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 2.02 · Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Pivotal Phase 3 enrollment completed, but topline data not expected until second half of 2027, delaying potential approval and commercialization
- EMA-required drug-substance characterization testing delayed Phase 3 enrollment authorization under EU Clinical Trial Regulation
- Single-source manufacturing for bel-sar regulatory materials, drug substance, and drug product heightens supply interruption risk
- Cash and marketable securities fund operations into first half of 2029, but additional capital needed to complete bel-sar development
- 2026 Sales Agreement permits up to $200.0 million in common-stock offerings, creating potential shareholder dilution
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no products approved for sale
- Net loss $32.1M vs $26.1M YoY, operating expenses $35.1M vs $27.9M
- R&D $24.7M vs $22.2M, clinical trials $9.3M vs $6.9M, strongest spending area
- Cash, equivalents and marketable securities $297.2M, funding operations into first half of 2029
- Operating cash use $88.8M vs $64.3M, financing provided $242.3M after $280.8M offering proceeds and $39.0M repurchase
AI summary of the AURA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release announces Aura Biosciences’ financial results for the quarter ended September 30, 2026
- Exhibit 99.1 contains the detailed quarterly financial results and management commentary
Item 8.01: Other Events
- Updated corporate presentation signals refreshed investor messaging around Aura’s pipeline, strategy, and development plans
- Company reiterates expected cash runway into the first half of 2029, a key financing-risk indicator for this clinical-stage biotech
Item EX-99.1: Item EX-99.1
- Phase 3 CoMpass fully treated 108 participants, with topline 15-month data targeted for 2H 2027
- FDA Special Protocol Assessment supports the planned trial design for a potential bel-sar BLA, but approval remains contingent on results
Item EX-99.2: Item EX-99.2
- Aura’s investor presentation highlights bel-sar as a potential first vision-preserving therapy for early choroidal melanoma, an indication with approximately 11,000 annual US/EU cases
- Phase 3 CoMpass trial fully enrolled 108 patients, with topline data expected in 2H 2027 under an FDA Special Protocol Assessment
Item 2.05: Costs Associated with Exit or Disposal Activities
- Workforce reduction of approximately 20% as Aura refocuses resources on ocular oncology
- NMIBC program resource allocation to be minimized, signaling reduced strategic emphasis on bladder cancer
Item EX-99.1: Item EX-99.1
- Phase 3 CoMpass fully enrolled with 108 patients; topline data remain targeted for 2H 2027 under an FDA SPA
- Ocular oncology becomes the core strategy; NMIBC investment reduced despite 81% three-month response and 69% complete response rates
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Susan Abu-Absi appointed COO effective August 10, 2026, adding an operational leader with prior biotech manufacturing and development experience
- COO compensation includes $520,000 base salary, 45% target annual bonus, and approximately 400,000 inducement shares
Item 8.01: Other Events
- Updated corporate presentation for investor and analyst meetings on August 11, 2026
- Presentation likely highlights bel-sar development, clinical programs, and strategic plans
Item EX-99.2: Item EX-99.2
- CoMpass Phase 3 trial fully enrolled with FDA SPA support, reducing design-related regulatory uncertainty
- Topline primary efficacy data targeted for 2H 2027, the key near-term catalyst for bel-sar
Item 2.02: Results of Operations and Financial Condition
- Aura Biosciences announced financial results for the quarter ended June 30, 2026
- Results were issued August 11, 2026, with detailed figures in Exhibit 99.1
Item 5.07: Submission of Matters to a Vote of Security Holders
- Stockholders approved increasing authorized common shares from 150 million to 500 million
- Expanded share capacity enables future financing, acquisitions, or strategic transactions, with potential dilution risk
AI summaries of AURA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AURA
Don't miss the next AURA filing
- Alerts as it files. A push when AURA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AURA, by share count.
- Ask anything. An AI agent that reads every AURA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Hopkins Janet Jill | Sell | Nov 16, 2026 | 16,903 | $7.05 |
| Person Julie | A | Sep 1, 2026 | 107,611 | - |
| Kratz Erica | A | Sep 1, 2026 | 100,885 | - |
| Hopkins Janet Jill | A | Sep 1, 2026 | 58,850 | - |
| Elazzouzi Amy | A | Sep 1, 2026 | 23,540 | - |
| Abu-Absi Susan | A | Sep 1, 2026 | 265,487 | - |
| Elazzouzi Amy | A | Sep 1, 2026 | 46,460 | - |
| Abu-Absi Susan | A | Sep 1, 2026 | 134,513 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$85.0M | -$96.1M | -$112.8M |
| Net Income | -$76.4M | -$86.9M | -$106.2M |
| Balance Sheet | |||
| Total Assets | $255.1M | $182.5M | $169.4M |
| Equity | - | $152.0M | $136.9M |
| ROE | - | -57.2% | -77.6% |
| Per Share | |||
| EPS | $-1.93 | $-1.75 | $-1.76 |
| Cash Flow | |||
| Operating CF | -$63.8M | -$79.8M | -$84.7M |
| CapEx | $709K | $1.3M | $447K |
Source: XBRL data in Aura Biosciences, Inc. (AURA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate AURA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 25 | $117.9M |
| Q2 2026 | 27 | $119.1M |
| Q1 2026 | 25 | $84.8M |
| Q4 2025 | 22 | $57.0M |
| Q3 2025 | 22 | $73.1M |
| Q2 2025 | 23 | $69.1M |
| Q1 2025 | 16 | $38.4M |
| Q4 2024 | 14 | $46.0M |
- State Street Corp+1.08M (+88%)
- BlackRock+716.6K (+15%)
- Goldman Sachs Group+480.3K (+103%)
- D.E. Shaw & Co+261.9K (+389%)
- Citadel Advisors LLC+252.6K (+487%)
- Vanguard Capital Management LLC−148.0K (-4%)
- T. Rowe Price Group−136.2K (-49%)
- AQR Capital Management−56.8K (-52%)
- Prudential Financial−38.3K (-78%)
- Renaissance Technologies LLC−34.1K (-20%)
- Millennium Management−617.5K
- FMR LLC (Fidelity)−255.3K
- PNC Financial Services−83
Source: 13F-HR filings on SEC EDGAR (aggregated from 174 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AURA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 16, 2026 | - | - | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jul 8, 2026 | - | - | - |
| 8-K | Jul 8, 2026 | - | Analysis | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 4 | May 19, 2026 | - | - | |
| SC 13G | May 12, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 8-K | May 11, 2026 | - | Analysis |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
AURA SEC filings: frequently asked questions
Are AURA insiders buying or selling?
In the last 90 days, Aura Biosciences, Inc. (AURA) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $119,166 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold AURA stock?
As of September 30, 2026, the largest Aura Biosciences, Inc. (AURA) holders among the 13F filers tracked by SignalX were BlackRock ($34.1 million), Vanguard Capital Management LLC ($24.8 million), State Street Corp ($14.5 million), Franklin Resources ($13.8 million), Goldman Sachs Group ($5.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did AURA report in its latest 8-K?
Aura Biosciences, Inc. (AURA) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 8.01 (Other Events). Press release announces Aura Biosciences’ financial results for the quarter ended September 30, 2026.
What are the latest AURA SEC filings?
Aura Biosciences, Inc. (AURA) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 16, 2026.
What is AURA's SEC CIK number?
Aura Biosciences, Inc. (AURA)'s SEC Central Index Key (CIK) is 1501796. EDGAR lists every AURA filing under that number.
Ask anything about AURA
The research agent reads AURA's filings, financials, insider trades and 13F holders, then answers with sources.